Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Cardiologists and the Cardiology of the Future. Vision and proposals of the Spanish Society of Cardiology for the Cardiology of the 21st Century.

Sánchez MA, Martín JJA, Fillat ÁC, Doblas JJG, Rivera LP, Goya IL, Rodrigo FR, Romo AÍ, Miguel CM, Masip AE, Melchor LS, Bueno H, Molina BD, Ferreira-González I, Elola Somoza FJ.

Rev Esp Cardiol (Engl Ed). 2019 Aug;72(8):649-657. doi: 10.1016/j.rec.2019.02.025. Epub 2019 Jul 13. English, Spanish.

PMID:
31311762
2.

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG.

Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.

3.

Cumulative advantages and social capabilities in scientific mobility in the Health Sciences: The Spanish case.

Aceituno-Aceituno P, Melchor L, Danvila-Del-Valle J, Bousoño-Calzón C.

PLoS One. 2017 Mar 15;12(3):e0173204. doi: 10.1371/journal.pone.0173204. eCollection 2017.

4.

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. Epub 2016 May 27.

5.

Wnt and Neuregulin1/ErbB signalling extends 3D culture of hormone responsive mammary organoids.

Jardé T, Lloyd-Lewis B, Thomas M, Kendrick H, Melchor L, Bougaret L, Watson PD, Ewan K, Smalley MJ, Dale TC.

Nat Commun. 2016 Oct 26;7:13207. doi: 10.1038/ncomms13207.

6.

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.

Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ.

J Clin Oncol. 2015 Nov 20;33(33):3911-20. doi: 10.1200/JCO.2014.59.1503. Epub 2015 Aug 17.

7.

APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma.

Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ.

Nat Commun. 2015 Apr 23;6:6997. doi: 10.1038/ncomms7997.

8.

Whole-exome DNA sequence analysis of Brca2- and Trp53-deficient mouse mammary gland tumours.

Francis JC, Melchor L, Campbell J, Kendrick H, Wei W, Armisen-Garrido J, Assiotis I, Chen L, Kozarewa I, Fenwick K, Swain A, Smalley MJ, Lord CJ, Ashworth A.

J Pathol. 2015 Jun;236(2):186-200. doi: 10.1002/path.4517. Epub 2015 Apr 2.

PMID:
25692405
9.

Biology and treatment of myeloma.

Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ.

Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S65-70. doi: 10.1016/j.clml.2014.06.011. Review.

PMID:
25486959
10.

Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations.

Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ.

Blood. 2015 Jan 29;125(5):831-40. doi: 10.1182/blood-2014-07-584268. Epub 2014 Nov 26.

11.

Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome.

Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, Jackson GH, Gregory WM, Owen RG, Child JA, Davies FE, Cavo M, Drayson MT, Morgan GJ.

Blood. 2014 May 29;123(22):3414-9. doi: 10.1182/blood-2013-12-542662. Epub 2014 Apr 14.

PMID:
24733348
12.

The impact of long-term lenalidomide exposure on the cellular composition of bone marrow.

Brioli A, Melchor L, Titley I, Vijayaraghavan G, Stephens C, Zeisig A, Pawlyn C, Cavo M, Morilla R, Davies FE, Morgan GJ.

Leuk Lymphoma. 2014 Nov;55(11):2665-8. doi: 10.3109/10428194.2014.900765. Epub 2014 Apr 22. No abstract available.

PMID:
24660850
13.

Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models.

Melchor L, Molyneux G, Mackay A, Magnay FA, Atienza M, Kendrick H, Nava-Rodrigues D, López-García MÁ, Milanezi F, Greenow K, Robertson D, Palacios J, Reis-Filho JS, Smalley MJ.

J Pathol. 2014 Jun;233(2):124-37. doi: 10.1002/path.4345.

PMID:
24615332
14.

The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.

Brioli A, Melchor L, Cavo M, Morgan GJ.

Br J Haematol. 2014 May;165(4):441-54. doi: 10.1111/bjh.12805. Epub 2014 Mar 2. Review.

PMID:
24580032
15.

Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma.

Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, Fryer RA, Johnson DC, Begum DB, Hulkki Wilson S, Vijayaraghavan G, Titley I, Cavo M, Davies FE, Walker BA, Morgan GJ.

Leukemia. 2014 Aug;28(8):1705-15. doi: 10.1038/leu.2014.13. Epub 2014 Jan 13.

PMID:
24480973
16.

Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ.

Leukemia. 2014 Feb;28(2):384-390. doi: 10.1038/leu.2013.199. Epub 2013 Jul 2.

17.

Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma.

Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE, Morgan GJ.

Blood. 2013 Jul 11;122(2):219-26. doi: 10.1182/blood-2013-03-487884. Epub 2013 May 22.

18.

The complex genetic landscape of familial breast cancer.

Melchor L, Benítez J.

Hum Genet. 2013 Aug;132(8):845-63. doi: 10.1007/s00439-013-1299-y. Epub 2013 Apr 5. Review.

PMID:
23552954
19.

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ.

Blood. 2012 Aug 2;120(5):1077-86. doi: 10.1182/blood-2012-03-412981. Epub 2012 May 9.

PMID:
22573403
20.

Gene amplification of the transcription factor DP1 and CTNND1 in human lung cancer.

Castillo SD, Angulo B, Suarez-Gauthier A, Melchor L, Medina PP, Sanchez-Verde L, Torres-Lanzas J, Pita G, Benitez J, Sanchez-Cespedes M.

J Pathol. 2010 Sep;222(1):89-98. doi: 10.1002/path.2732.

PMID:
20556744
21.

Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes.

Melchor L, Saucedo-Cuevas LP, Muñoz-Repeto I, Rodríguez-Pinilla SM, Honrado E, Campoverde A, Palacios J, Nathanson KL, García MJ, Benítez J.

Breast Cancer Res. 2009;11(6):R86. doi: 10.1186/bcr2456. Epub 2009 Dec 8.

22.

Highway to heaven: mammary gland development and differentiation.

Melchor L, Smalley MJ.

Breast Cancer Res. 2008;10(5):305. doi: 10.1186/bcr2147. Epub 2008 Oct 6.

23.

An integrative hypothesis about the origin and development of sporadic and familial breast cancer subtypes.

Melchor L, Benítez J.

Carcinogenesis. 2008 Aug;29(8):1475-82. doi: 10.1093/carcin/bgn157. Epub 2008 Jul 1. Review.

PMID:
18596026
24.

Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer.

Melchor L, Honrado E, Huang J, Alvarez S, Naylor TL, García MJ, Osorio A, Blesa D, Stratton MR, Weber BL, Cigudosa JC, Rahman N, Nathanson KL, Benítez J.

Clin Cancer Res. 2007 Dec 15;13(24):7305-13.

25.

Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.

Melchor L, Honrado E, García MJ, Alvarez S, Palacios J, Osorio A, Nathanson KL, Benítez J.

Oncogene. 2008 May 15;27(22):3165-75. Epub 2007 Dec 10.

PMID:
18071313
26.

Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families.

Honrado E, Osorio A, Milne RL, Paz MF, Melchor L, Cascón A, Urioste M, Cazorla A, Díez O, Lerma E, Esteller M, Palacios J, Benítez J.

Mod Pathol. 2007 Dec;20(12):1298-306. Epub 2007 Sep 21.

27.

Genomic analysis of the 8p11-12 amplicon in familial breast cancer.

Melchor L, Garcia MJ, Honrado E, Pole JC, Alvarez S, Edwards PA, Caldas C, Brenton JD, Benítez J.

Int J Cancer. 2007 Feb 1;120(3):714-7.

28.

A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriers.

Osorio A, Martínez-Delgado B, Pollán M, Cuadros M, Urioste M, Torrenteras C, Melchor L, Díez O, De La Hoya M, Velasco E, González-Sarmiento R, Caldés T, Alonso C, Benítez J.

Hum Mutat. 2006 Mar;27(3):242-8.

PMID:
16419081
29.

The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumors.

Melchor L, Alvarez S, Honrado E, Palacios J, Barroso A, Díez O, Osorio A, Benítez J.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8577-84.

30.

About the origin and development of hereditary conventional renal cell carcinoma in a four-generation t(3;8)(p14.1;q24.23) family.

Valle L, Cascón A, Melchor L, Otero I, Rodríguez-Perales S, Sánchez L, Cruz Cigudosa J, Robledo M, Weber B, Urioste M, Benítez J.

Eur J Hum Genet. 2005 May;13(5):570-8.

31.

Understanding the cytological diploidization mechanism of polyploid wild wheats.

Cuñado N, Blazquez S, Melchor L, Pradillo M, Santos JL.

Cytogenet Genome Res. 2005;109(1-3):205-9.

PMID:
15753578
32.

A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylation.

Alvarez S, Diaz-Uriarte R, Osorio A, Barroso A, Melchor L, Paz MF, Honrado E, Rodríguez R, Urioste M, Valle L, Díez O, Cigudosa JC, Dopazo J, Esteller M, Benitez J.

Clin Cancer Res. 2005 Feb 1;11(3):1146-53.

33.

Analysis of myelodysplastic syndromes with complex karyotypes by high-resolution comparative genomic hybridization and subtelomeric CGH array.

Martínez-Ramírez A, Urioste M, Melchor L, Blesa D, Valle L, de Andrés SA, Kok K, Calasanz MJ, Cigudosa JC, Benítez J.

Genes Chromosomes Cancer. 2005 Mar;42(3):287-98.

PMID:
15611930

Supplemental Content

Loading ...
Support Center